|
|
Blood, 15 February 2008, Vol. 111, No. 4, pp. 2155-2157.
Prepublished online as a Blood First Edition Paper on December 19, 2007; DOI 10.1182/blood-2007-09-115030.
 Previous Article | Next Article 
Submitted September 28, 2007
Accepted November 27, 2007
The specificity of JAK3 kinase inhibitors
Paul S. Changelian*, Deborah Moshinsky, Cyrille F. Kuhn, Mark E. Flanagan, Michael J. Munchhof, Thomas M. Harris, Jonathan L. Doty, Jianmin Sun, Craig R. Kent, Kelly S. Magnuson, David G. Perregaux, Perry S. Sawyer, and Elizabeth M. Kudlacz
Pfizer Global Research and Development, Groton, CT, United States
* Corresponding author; email: changelianps{at}gmail.com.
PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690,550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection. PF-956980 has been evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3. Cellular and whole blood activity of this compound parallels its potency and selectivity in enzyme assays. It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice. We compared two commercially available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochemical and cellular assays and found them to be neither potent nor selective for JAK3. Both were found to be nanomolar inhibitors of the EGF receptor family of kinases. As these compounds have been used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Carbonnelle, M. Duflos, P. Marchand, C. Chauvet, J.-Y. Petit, and F. Lang
A Novel Indole-3-propanamide Exerts Its Immunosuppressive Activity by Inhibiting JAK3 in T Cells
J. Pharmacol. Exp. Ther.,
November 1, 2009;
331(2):
710 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Y. Chang, F. Zhao, X. He, H. Ren, S. Braselmann, V. Taylor, J. Wicks, D. G. Payan, E. B. Grossbard, P. R. Pine, et al.
JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
J. Immunol.,
August 1, 2009;
183(3):
2183 - 2192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Lawendy, S. Krishnaswami, R. Wang, D. Gruben, C. Cannon, S. Swan, and G. Chan
Effect of CP-690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers
J. Clin. Pharmacol.,
April 1, 2009;
49(4):
423 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Johnson, N. Shah, A. A. Bajer, and T. W. LeBien
IL-7 Activates the Phosphatidylinositol 3-Kinase/AKT Pathway in Normal Human Thymocytes but Not Normal Human B Cell Precursors
J. Immunol.,
June 15, 2008;
180(12):
8109 - 8117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
